Chang YS - Search Results

1

Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea.

Lee SY, Choi CM, Chang YS, Lee KY, Kim SJ, Yang SH, Ryu JS, Lee JE, Lee SY, Park JY, Kim YC, Oh IJ, Jung CY, Lee SH, Yoon SH, Choi J, Jang TW. Lee SY, et al. Among authors: chang ys. Transl Lung Cancer Res. 2021 Dec;10(12):4353-4367. doi: 10.21037/tlcr-21-501. Transl Lung Cancer Res. 2021. PMID: 35070746 Free PMC article.

2

Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer.

Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK. Chang YS, et al. Among authors: chang j. Lung Cancer. 2007 Sep;57(3):373-80. doi: 10.1016/j.lungcan.2007.04.005. Epub 2007 May 21. Lung Cancer. 2007. PMID: 17513004

3

BCL2-like 11 intron 2 deletion polymorphism is not associated with non-small cell lung cancer risk and prognosis.

Cho EN, Kim EY, Jung JY, Kim A, Oh IJ, Kim YC, Chang YS. Cho EN, et al. Among authors: chang ys. Lung Cancer. 2015 Oct;90(1):106-10. doi: 10.1016/j.lungcan.2015.07.017. Epub 2015 Aug 1. Lung Cancer. 2015. PMID: 26271547

4

Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma.

Chang YS, Choi CM, Lee JC. Chang YS, et al. Tuberc Respir Dis (Seoul). 2016 Oct;79(4):248-256. doi: 10.4046/trd.2016.79.4.248. Epub 2016 Oct 5. Tuberc Respir Dis (Seoul). 2016. PMID: 27790276 Free PMC article. Review.

5

Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor.

Goag EK, Lee JM, Chung KS, Kim SY, Leem AY, Song JH, Jung JY, Park MS, Chang YS, Kim YS, Chang J, Kim EY. Goag EK, et al. Among authors: chang j, chang ys. J Cancer. 2018 Mar 2;9(6):1113-1120. doi: 10.7150/jca.21650. eCollection 2018. J Cancer. 2018. PMID: 29581791 Free PMC article.

6

Tumor clonal status predicts clinical outcomes of lung adenocarcinoma with EGFR-TKI sensitizing mutation.

Kim EY, Lee SH, Kim A, Kim T, Chang YS. Kim EY, et al. Among authors: chang ys. J Cancer. 2019 Aug 29;10(22):5549-5556. doi: 10.7150/jca.32897. eCollection 2019. J Cancer. 2019. PMID: 31632498 Free PMC article.

7

Presence of mEGFR ctDNA predicts a poor clinical outcome in lung adenocarcinoma.

Kim T, Kim EY, Lee SH, Kwon DS, Kim A, Chang YS. Kim T, et al. Among authors: chang ys. Thorac Cancer. 2019 Dec;10(12):2267-2273. doi: 10.1111/1759-7714.13219. Epub 2019 Oct 24. Thorac Cancer. 2019. PMID: 31647198 Free PMC article.

8

Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation-Positive Lung Adenocarcinoma.

Kim T, Cha YJ, Chang YS. Kim T, et al. Among authors: chang ys. Tuberc Respir Dis (Seoul). 2020 Jan;83(1):51-60. doi: 10.4046/trd.2019.0026. Tuberc Respir Dis (Seoul). 2020. PMID: 31905432 Free PMC article.

9

Recent advances in diagnostic technologies in lung cancer.

Park HJ, Lee SH, Chang YS. Park HJ, et al. Among authors: chang ys. Korean J Intern Med. 2020 Mar;35(2):257-268. doi: 10.3904/kjim.2020.030. Epub 2020 Feb 28. Korean J Intern Med. 2020. PMID: 32131569 Free PMC article. Review.

10

Compared to plasma, bronchial washing fluid shows higher diagnostic yields for detecting EGFR-TKI sensitizing mutations by ddPCR in lung cancer.

Lee SH, Kim EY, Kim T, Chang YS. Lee SH, et al. Among authors: chang ys. Respir Res. 2020 Jun 9;21(1):142. doi: 10.1186/s12931-020-01408-x. Respir Res. 2020. PMID: 32517757 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,261 results

Search Page

Filters